Cerbomed appoints new Chairman and expands Advisory Board

ERLANGEN, Germany--(BUSINESS WIRE)-- Cerbomed GmbH, today announced the appointment of Dr. Matthias Kromayer as Chairman of its Advisory Board. In line with cerbomed’s transition from an innovative medical engineering company to a commercial, medical device company, cerbomed also appointed Bernd von Polheim, Dierk Neugebauer and Dr. Peter Terhart to the Company’s Advisory Board. Under the leadership of Dr. Kromayer, the new Advisory Board will work closely with Dr. Andreas Hartlep, CEO of cerbomed, to execute the company’s product commercialization plans.

"I very much look forward to working with Andreas and his team", said Dr. Kromayer, a representative of MIG AG, the company’s major shareholder. “I am certain our expanded Advisory Board will provide the support to propel cerbomed toward its goal to become the leader in the non-invasive neurostimulation field.”

Cerbomed’s newly appointed Board members contribute extensive executive management experience in the medical device industry. Mr. von Polheim is the former VP GE Healthcare Europe and has an extensive network in the medical device industry. Dierk Neugebauer served as Managing Director, Market Access Novartis Pharma, Germany, and contributes over 15 years of senior management experience in both the pharmaceutical and statutory health insurance industries. Dr. Peter Terhart serves as CEO of S-Refit AG and is among Germany’s leading venture capitalists.

"I look forward to working closely with Matthias and I welcome Bernd von Polheim, Dierk Neugebauer und Dr. Peter Terhart to our Advisory Board. Their experiences and access to resources will support cerbomed to successfully execute challenges ahead.” commented Dr. Andreas Hartlep. “On behalf of the Board and my colleagues at cerbomed, I also extend my gratitude for the insights and services contributed by Jürgen Kosch and Christian Müller who have decided to leave the Advisory Board.”

About cerbomed
Cerbomed is a privately held, medical device company based in Erlangen, Germany, aiming to become the leader for the development of non-invasive Vagus Nerve Stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.

About t-VNS
t-VNS is applied to the left outer ear, over the auricular branch of the vagus nerve, where it stimulates the nerve transcutaneously. Cerbomed therefore expects t-VNS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies.



CONTACT:

cerbomed
Dr. Martin Hyca, Director Marketing
+49 9131 920 276-30
[email protected]

KEYWORDS:   Europe  Germany

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Professional Services  Finance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.